IP Library Granted Patent US 9,283,200
Granted Patent B2
US 9,283,200 · App. 14/515,298 · Granted Mar 15, 2016

Treatment of medium-chain acyl-CoA dehydrogenase deficiency

Inventors: Al-Walid Mohsen Mohamed (Carnagie, PA); Gerard Vockley (Pittsburgh, PA)
A61K31/192A61K31/216
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,283,200
App. No.
14/515,298
Granted
Mar 15, 2016
Kind
B2
Abstract

The present invention provides for methods and compositions for treating medium chain acyl-CoA dehydrogenase deficiency. It is based, at least in part, on the discovery that phenylbutyrate can serve as a substrate for medium chain acyl-CoA dehydrogenase. In non-limiting embodiments, phenylbutyrate and/or another source of phenylacetate is administered as a chaperone treatment to patients suffering from medium chain acyl-CoA dehydrogenase deficiency.

Claims (12)

1. A method for treating medium chain acyl-CoA dehydrogenase deficiency in a subject suffering therefrom comprising administering, to the subject, an effective amount of phenylbutyrate and/or another source of phenylacetate as a regular therapy regimen.

2. The method of claim 1 , where phenylbutyrate is administered as a phenylbutyrate salt.

3. The method of claim 2 , where the salt is sodium phenylbutyrate.

4. The method of claim 1 , where triphenylbutyrylglycerol is administered to the subject as a source of phenylacetate.

5. The method of claim 1 , where a mixture of sodium benzoate and sodium phenylacetate is administered to the subject as a source of phenylacetate.

6. A method for treating medium chain acyl-CoA dehydrogenase deficiency in a subject suffering therefrom comprising administering, to the subject, an effective amount of phenylbutyrate and/or another source of phenylacetate when the subject is at metabolic risk.

7. The method of claim 6 , where the subject is at metabolic risk because of an infection.

8. The method of claim 6 , where the subject is at metabolic risk because of a fasting interval.

9. The method of claim 6 where phenylbutyrate is administered as a phenylbutyrate salt.

10. The method of claim 9 , where the salt is sodium phenylbutyrate.

11. The method of claim 6 , where triphenylbutyrylglycerol is administered to the subject as a source of phenylacetate.

12. The method of claim 6 , where a mixture of sodium benzoate and sodium phenylacetate is administered to the subject as a source of phenylacetate.

Assignments (2)
CONFIRMATORY LICENSE Recorded Aug 3, 2015
From: UNIVERSITY OF PITTSBURGH
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 036245/0231 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 8, 2015
From: MOHAMED, AL-WALID MOHSEN; VOCKLEY, GERARD
To: UNIVERSITY OF PITTSBURGH ? OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
Reel/Frame 034665/0365 →
Continuity (3)
Continuation PCTUS2013036739 · Apr 16, 2013
Provisional Application 61624864 · Apr 16, 2012
Related Publication 20150216824A1 · Aug 6, 2015